title: Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
abstract: Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.2-102.3; P < .02), cirrhosis, (OR, 8.8; 95% CI, 1.2-104.2; P<.02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly.
authors.affiliation: INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France. firouze.bani-sadr@tnn.ap-hop-paris.fr
authors.forename: Firouzé
authors.initials: F
authors.lastname: Bani-Sadr
authors.forename: Fabrice
authors.initials: F
authors.lastname: Carrat
authors.forename: Eric
authors.initials: E
authors.lastname: Rosenthal
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
authors.forename: Patrice
authors.initials: P
authors.lastname: Morand
authors.forename: Françoise
authors.initials: F
authors.lastname: Lunel-Fabiani
authors.forename: Mojgan
authors.initials: M
authors.lastname: Bonarek
authors.forename: Nathalie
authors.initials: N
authors.lastname: Colin de Verdiere
authors.forename: Gilles
authors.initials: G
authors.lastname: Pialoux
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
authors.forename: Christian
authors.initials: C
authors.lastname: Perronne
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D017093:Liver Failure / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b